• Urologists positive about abiraterone integration

    6 days ago - By Modern Medicine

    More than 96% of urologists surveyed said that incorporating abiraterone acetate treatment into practice for patients with metastatic castrate-resistant prostate cancer is easy or manageable after overcoming initial barriers, according to new research presented at the Genitourinary Cancers Symposium in Orlando, FL.
    Lead author Andrew Feifer, MD, staff uro-oncologist at Trillium Health Partners and associate staff at University Health Network, Toronto, told Urology Times that he and his co-authors set out to better understand whether urologists' real-world interpretations of incorporating...
    Read more ...